EXECUTIVE DIRECTOR, LISA BUTLER DISCUSSES LEGISLATION, FOR PATIENTS ON MEDICARE, WITH NHC

Executive Director, Lisa Butler discusses legislation, for patients on Medicare, with NHC. Full article here:https://nationalhealthcouncil.org/blog/guest-post-legislation-needed-to-improve-access-to-vital-treatment-for-medicare-rare-disease-patients/

Read More about EXECUTIVE DIRECTOR, LISA BUTLER DISCUSSES LEGISLATION, FOR PATIENTS ON MEDICARE, WITH NHC

WHY RARE CONDITIONS DESERVE ATTENTION AND RECOGNITION AS A GLOBAL HEALTH CONCERN

As Rare Disease Day is approaching, CSL Behring is in touch with leaders of patient advocacy groups to explain why rare conditions deserve attention and recognition as a global health…

Read More about WHY RARE CONDITIONS DESERVE ATTENTION AND RECOGNITION AS A GLOBAL HEALTH CONCERN

SoHo Regulation Update

Following the provisional political agreement reached on 14 December 2023, the EU institutions finalized the text for the Regulation which now enters the final stages of official approval. The text…

Read More about SoHo Regulation Update

European Commission approves Takeda’s HYQVIA

In the news today, the European Commission approves Takeda’s HYQVIA, a new maintenance therapy for patients with CIDP. The Foundation advocates for access to all products at all points of…

Read More about European Commission approves Takeda’s HYQVIA

TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use…

Read More about TAKEDA receives positive CHMP opinion for HYQVIA® as maintenance therapy in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

SoHo Regulation in Trilogue Negotiation

On 12 September 2023, the European Parliament adopted the report on new rules governing the use of so-called substances of human origin (SoHO) intended for human application.  The Council still needs to…

Read More about SoHo Regulation in Trilogue Negotiation

2024 Research Grant Opportunities

As part of the GBS|CIDP Foundation International’s mission to provide education and support research, we offer research grants to qualified applicants. Through the generosity of these many individual contributors, to…

Read More about 2024 Research Grant Opportunities

European Parliament adopts substances of human origin (SoHO) 

European Parliament adopts substances of human origin (SoHO)  On 12 September 2023, the European Parliament adopted the report on new rules governing the use of so-called substances of human origin…

Read More about European Parliament adopts substances of human origin (SoHO) 

Statement regarding GBS alert in Peru

Statement regarding GBS alert in Peru July 10, 2023 July 10, 2023 The Foundation and its Global Medical Advisory Board are aware that Peru has issued a statement of emergency…

Read More about Statement regarding GBS alert in Peru

2023 Virtual Summit

2023 Virtual Summit, Life After Diagnosis Back by popular demand, our 2023 Virtual Summit will feature a wide range of educational panels and presentations, as recorded at the 2022 Ponte Vedras, FL Patient Symposium &…

Read More about 2023 Virtual Summit